Recombinant HIV-1 envelope proteins and their use

US12145968B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Peter Kwong · Washington, US
• Marie Pancera · Seattle, US
• Tongqing Zhou · Boyds, US
• Ivelin Georgiev · Nashville, US
• Michael Gordon Joyce · Washington, US
• Priyamvada Acharya · Fort Lee, US
• Jason Gorman · Washington, US
• Yongping Yang · Potomac, US
• Guillaume Stewart-Jones · Cambridge, US
• Rita Chen · Taipei, TW
• Gwo-Yu Chuang · Rockville, US
• John Mascola · Rockville, US
• Baoshan Zhang · Bethesda, US
• Cheng Cheng · Bethesda, US
• Mallika Sastry · Rockville, US
• Aliaksandr Druz · Germantown, US

Key dates

• Filing date: Oct 3, 2022
• Grant date: Nov 19, 2024
• Expiry date: Oct 3, 2042

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2469/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.